Microphysiological models for the assessment of pulmonary concentration of inhaled aerosols

吸入气雾剂是肺部疾病的首选治疗方法。尽管它们具有常见的治疗用途，但其肺部药代动力学特征存在许多不确定性，这与测量特性的难度有关。了解沉积区域和局部渗透率将有助于阐明吸入化合物的吸收过程。鉴于此，需要一种新的模型。为了降低成本和动物负担，体外测定是一种简单的解决方案。一种被称为器官芯片的新兴技术开辟了生物相关研究工具的新领域，允许在微观尺度上进行器官的 3D 翻译。该提案的核心是对肺部药代动力学知识差距方面的最新技术进行回顾，并为构建体外模型提供要素，以解决这些问题。

Inhaled aerosols are the treatment of choice for pulmonary diseases. Despite their common therapeutic use, many uncertainties regarding their pulmonary pharmacokinetic profile exist, linked to the difficulty of measuring properties in place. Knowing the region of deposition and local rate of permeation would allow elucidation of absorption processes for inhaled compounds. Given that, a new model is required. To cut costs and animal burden, in vitro assay is a straightforward solution. An emerging technology known as organ-on-chip has opened a new frontier of biorelevant investigative tools, allowing a 3D translation of organs on a microscale. The core of this proposal is to present a review of the current state-of-the-art in terms of knowledge gaps in pulmonary pharmacokinetics and provide elements for the construction of an in vitro model, to address such questions.